St. Jude Clinical Trials
3CAR: B7-H3-specific CAR T-cell Therapy for Children and Young Adults with Solid Tumors
B7-H3-specific Chimeric Antigen Receptor Autologous T-cell Therapy for Pediatric Patients with Solid Tumors (3CAR)
Diseases Treated:
Solid Tumors
Eligibility:
Inclusion criteria include:
- 21 years old or younger
- Relapsed or refractory B7-H3-positive solid tumor
ANGIO-A: Study of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Children and Young Adults with Solid Tumors
Safety and Tolerability of Oral Cyclophosphamide and Sorafenib with Intravenous Bevacizumab with the Addition of Atezolizumab in Pediatric Solid Tumor Patients
Diseases Treated:
Solid tumors
Hepatocellular carcinoma
Fibrolamellar hepatocellular carcinoma
Sarcomas
Malignant rhabdoid tumors
Desmoplastic small round cell tumors
Eligibility:
Part 1
- 1–30 years old
- Diagnosis of a solid tumor that has grown or has come back after treatment
- Tumor accessible through biopsy
Part 2
- 1–30 years old
- Diagnosis of:
- Hepatocellular carcinoma that has grown or has come back after treatment
- Fibrolamellar hepatocellular carcinoma
- Desmoplastic small round cell tumor
- Malignant rhabdoid tumor that is not in the central nervous system
- Tumor accessible through biopsy
AOST2032: Cabozantinib with Chemotherapy for Osteosarcoma
A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Diseases Treated:
Eligibility:
FLOPET: PET Scan Studies to Analyze Neuroblastoma and Pheochromocytoma Tumors
18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
Diseases Treated:
Neuroblastoma, pheochromocytoma
Eligibility:
This study is open to St. Jude patients only.
- Known or suspected neuroblastoma or pheochromocytoma
- At least 1 year old
ONITT: Study of Onivyde with Talazoparib or Temozolomide in Children and Young Adults with Recurrent/Refractory Solid Tumors and Ewing Sarcoma
Phase 1/2 Study of Onivyde in combination with Talazoparib or Temozolomide in Children and Young Adults with Recurrent/Refractory Solid Tumors and Ewing Sarcoma
Diseases Treated:
Eligibility:
- Ages 12 months old to 30 years
- Diagnosed with recurrent or refractory solid tumor (Phase 1)
- Diagnosed with recurrent or refractory Ewing sarcoma (Phase 2)
RBAPP: Smartphone App for Retinoblastoma
Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma
Diseases Treated:
Eligibility:
This study is currently open only to patients at St. Jude Children's Research Hospital.
- 7 years old or younger
- Part I
- Diagnosed with retinoblastoma and has not received any treatment OR
- Diagnosed with cataracts and has not received any treatment OR
- Diagnosed with glaucoma and has not received any treatment
- Part II
- Referred to an eye doctor to check for leukocoria or other eye conditions
- Part III
- Diagnosed with retinoblastoma and is receiving treatment
Collaborative Clinical Trials
LOXORET: Phase I/II Study of LOXO-292 (Selpercatinib) in Patients with Advanced RET-Altered Solid Tumors or Brain Tumors
Diseases Treated:
Solid tumors, Brain tumors
Eligibility:
- 6 months to 21 years old
- Solid tumor or brain tumor that has progressed or spread
- Failed standard treatment
- RET gene alteration
MEKPEM: A Phase I/II trial of MK-3475 (pembrolizumab) in children’s solid tumors and lymphomas
Diseases Treated:
Advanced melanoma or PD-L1 positive advanced relapsed or refractory solid tumor or lymphoma or high-grade glioma
Eligibility:
- Between 6 months and 18 years old with diagnosis of MSI-H solid tumor OR
- Between 12 years and 18 years old with diagnosis of melanoma OR
- Between 3 and 18 years old with relapsed or refractory classical Hodgkin lymphoma OR
- Between 12 and 18 years old with a diagnosis of Stage IIB, IIC, III, or IV melanoma, who had prior surgery to remove the tumor, but no other treatment (including radiation), no metastatic disease, and who have completely recovered.
- Negative pregnancy test 72 hours prior to medication administration in participants of child-bearing potential
- Appropriate liver and kidney functions
NBL1232: Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-High Risk Neuroblastoma
Diseases Treated:
Neuroblastoma, ganglioneuroblastoma
Eligibility:
- Participant has been enrolled on ANBLB1 (ANBL00B1).
- Participant has newly diagnosed MYCN non-amplified neuroblastoma or MYCN non-amplified ganglioneuroblastoma.
- Participant is less than 12 months (Group A) and less than 18 months (Group B and Group C) of age at diagnosis.
Adrenocortical Tumors and International Pediatric Adrenocortical Tumor Registry (IPACTR)
The International Pediatric Adrenocortical Tumor Registry (IPACTR) contains data about children and teens who have adrenocortical tumor or ACT.
ACT is a rare type of cancer. It affects a very small number of children each year. That small number makes getting data difficult. Scientists at St. Jude started collecting details about children around the world who have had ACT.
The result is IPACTR. Experts use the IPACTR data to help understand ACT and help design research studies that aim to find new and better treatments.